Skip to main content
Download PDF

Examining the cross-sectional relationship of platelet/high-density lipoprotein cholesterol ratio with depressive symptoms in adults in the United States

BMC Psychiatry volume 24, Article number: 427 (2024) Cite this article

Abstract

Aims

Herein, we examined the correlation between platelet/high-density lipoprotein cholesterol ratio (PHR) and symptoms of depression among United States adults.

Methods

Data acquired from the 2007–2018 National Health and Nutrition Examination Survey, involving individuals ≥ 20 years of age, with available PHR and depression diagnosis information. We employed weighted uni- and multivariable logistic regression analyses to assess the distinct correlation between PHR and depressive symptoms. Additionally, we conducted subgroup, interaction, and restricted cubic spline analyses.

Results

In all, 28,098 subjects were recruited for analysis, with 8.04% depression status and 19.31 ± 0.11 mean PHR value. Depressive symptoms increased with higher quartiles of PHR. Following fully confounder adjustments in model 2, participants with the largest PHR quartiles exhibited a 53% (OR: 1.53, 95%CI: 1.00–2.33, P = 0.05) raised depressive symptoms, relative to participants with least PHR quartiles. Based on the two-piece-wise regression, the breakpoint was PHR = 23.76, and a positive association was more evident when PHR < 23.76 (OR = 1.06, 95%CI: 1.02–1.10, P = 0.01). When PHR ≥ 23.76, the correlation disappeared (P = 0.85). Using subgroup and interaction analyses, we revealed a positive relationship between PHR and depressive symptoms almost consistent among various population settings.

Conclusions

A convenient biomarker, the PHR was independently associated with an increased risk of depressive symptoms and may be a promising new bioindicator for the prediction of depression diagnosis.

Peer Review reports

Introduction

Depression is a globally widespread phenomenon which accompanies disinterest in daily activities, insomnia, loss of life pleasures, and emergence of suicidal interests. This condition influences both mental and physical health [1]. Statistics from the global burden of disease revealed a sharp rise (49.86%) in global depression incidences from 172 million in 1990 to 258 million in 2017 [2]. Moreover, based on World Health Organization (WHO) reports, depression currently ranks third among the leading causes of the global disease burden, and it is projected to become the foremost cause of burden of disease by 2030 due to its high incidence and its significant contribution to increased risk of disability and mortality [1]. Regrettably, even in the advent of new anti-depression therapies, the depressive recurrence rate remains elevated, and close to 80% patients experience a second episode [3]. Hence, it is critical to establish novel bioindicators of depression risk to enhance depression prevention and intervention.

Till date, there is no consensus on depression pathophysiology. However, emerging evidences suggest a strong role of inflammation in depression etiology [4, 5]. For example, one study showed that pro-inflammatory cytokine administration in a clinical setting augments depressive symptoms [6]. Research has also indicated that immune mediators might influence neurotransmission, neural activity, and neuroendocrine pathways, potentially contributing to major depression [7]. Moreover, based on certain clinical investigations, individuals suffering from autoimmune diseases and diabetes are more prone to developing depression [8,9,10]. Patients with depression often exhibit marked alterations in the peripheral and/or central inflammation [11, 12]. Moreover, several studies employed anti-inflammatory intervention to reduce depressive symptoms [13]. Thus, the role of inflammation in depression has garnered considerable attention. Some investigations have been conducted into the correlation between depression and inflammatory indicators like C-reactive protein (CRP), tumor necrosis factor-alpha (TNF-a), and interleukin-6 (IL-6) [14,15,16]. Considering these evidences, there is a clear association between inflammation and depression that can potentially be harnessed to treat or prevent depression.

The platelet/high-density lipoprotein cholesterol ratio (PHR) is a relatively new integrated assessment of inflammatory and hypercoagulability markers [17, 18]. Platelets release proinflammatory cytokines which promote the emergence and progression of inflammatory diseases. Upregulated and active platelets potentially give rise to, sustain, and regulate inflammatory responses among depressed patients [19]. Dietrich-Muszalska et al. demonstrated that active platelets increase inflammation-mediated blood platelet accumulation among patients suffering from mental disease [20]. High-density lipoprotein cholesterol (HDL-C) protects against atherogenesis and oxidative stress among cardiovascular disease patients [21], in addition to its role in anti-platelet, other anti-thrombotic [22, 23], and anti-inflammatory activities [24]. Nonetheless, there is much controversy in the potential HDL-C and depression link. One prospective investigation involving 246 subjects revealed that the HDL-C content is inversely proportional to depression severity [25]. Maes and colleagues discovered that lower serum HDL-C levels could serve as markers for major depression and suicidal behavior in depressed men, likely induced by the immune/inflammatory response in depression and associated with impaired reverse cholesterol transport from body tissues to the liver [26]. Conversely, a cross-sectional investigation reported a strong positive correlation between enhanced HDL-C levels and depression in both genders [27]. Moreover, a meta-analysis uncovered a correlation between high levels of HDL-C and increased depression levels, particularly among women [28]. Until now, there are no reports evaluating the association between PHR and depression. Therefore, as a newly defined systematic inflammatory marker, the PHR significance in depression requires additional exploration.

In this report, we hypothesized a possible relationship between PHR and depressive symptoms. To assess this relationship, we employed a large patient population with extensive relevant data, and adjusted for confounders, as appropriate. The conclusions of this study will enhance the mechanistic knowledge behind the inflammatory association of depression, as well as identification of robust bioindicators of this life-altering condition.

Materials and methods

Sample population and data acquisition

To conduct this retrospective analysis, data was sourced from the 2007–2018 National Health and Nutrition Examination Survey (NHANES, CDC, https://www.cdc.gov/nchs/nhanes/index.htm). NHANES utilizes an extensive, multistep, probability-clustering technique to obtain information for evaluation regarding the health and nutritional distribution among US adults and children. Its sampling approach utilized subjected from varied racial and ethnic backgrounds, including non-Hispanic black, non-Hispanic white, Mexican American, and so on. The overall participants in NHANES were 34,770 individuals ≥ 20 years of age. For this investigation, we eliminated some subjects as follows: those with missing depression-related symptoms data (n = 4863), pregnant women (n = 323), unavailable platelet counts (n = 1107), and missing HDL-C contents (n = 379). Following screening based on our strict inclusion and exclusion guidelines, we were left with 28,098 study subjects (Fig. 1). NHANES procedure received authorization from the National Center for Health Statistics (NCHS) Ethics Committee, and acquired informed consent from subjects prior to the initiation of study [29]. All acquired data were from the aforementioned open access database and can be accessed from other sources as well [30].

Fig. 1
figure 1

Representation of study design. Abbreviations NHANES, National Health and Nutrition Examination Survey; HDL-C, High-density lipoprotein cholesterol

Full size image

Results

Descriptive analysis

The clinical and biochemical profiles of subjects with/without elevated depressive symptoms were presented in Table 1. In all, 28,098 subjects were recruited for analysis, with 47.91 ± 0.24 years average age, 19.31 ± 0.11 average PHR index, average overall depression prevalence of 8.03% and increased with the rising PHR quartiles (Quartile 1: 5.99%, Quartile 2: 7.72%, Quartile 3: 8.69%, Quartile: 9.81%, Supplementary Table 1). In individuals with elevated or non-elevated depressive symptoms, except for age, LDL-C and fasting TC (P > 0.05), marked alterations were observed in platelet counts, HDL-C contents, gender, race, marital status, education level, family-PIR, BMI, diet status, smoking status, alcohol usage, vigorous recreational activities, sleep disorder, DM, hypertension, CKD and ASCVD (all P < 0.05).

Table 1 Initial descriptions of participants between with and without elevated depressive symptoms from the 2007–2018 cycles
Full size table
Fig. 2
figure 2

Restricted cubic spline analysis of the association between PHR values and depressive symptoms. Age, gender, race, education level, BMI (body mass index), marital status, family PIR (body mass index), smoking status, alcohol use, recreational activities, diet status, sleep disorder, DM (diabetes mellitus), hypertension, CKD (chronic kidney disease), ASCVD (arteriosclerotic cardiovascular disease), TC (fasting total cholesterol), LDL-C (low-density lipoprotein cholesterol) were all adjusted. OR, odds ratio; CI, confidence interval; Ref, reference

Full size image

Definition of PHR Index

Herein, PHR served as the exposure variable. Given that PHR values have considerable variability, PHR transformation was used instead. To calculate PHR index, we divided the platelet counts by HDL-C content, then divided the quotient by 10 [18].

Assessment of depression symptoms

Depressive symptoms evaluation in NHANES utilized the 2007–2018 Patient Health Questionnaire-9 (PHQ-9). PHQ-9 (consisting of 9 items) was employed for depression screening in primary care settings, using a 4-point scale to quantify the responses (not at all = 0, several days = 1, over half of all days = 2, almost daily = 3). To compute the PHQ-9 score, all 9 items were added; elevated scores represented more severe depression symptoms; whereas, 0 and 27 were the minimum and maximum scores, respectively. Depression status was categorized into 4 groups: mild [5,6,7,8,9], moderate [10,11,12,13,14], moderate to severe [15,16,17,18,19], and severe [20,21,22,23,24,25,26,27]. A binary variable indicating no depression (PHQ-9 score < 10) or elevated depressive symptoms (PHQ-9 score ≥ 10) was created using a threshold score of 10; with 88% sensitivity and specificity [31,32,33]. The employed questionnaire can be accessed at https://wwwn.cdc.gov/Nchs/Nhanes/2013-2014/DPQ_H.htm.

Biochemical parameters

Blood samples were collected for biochemical assessment at a mobile examination center (MEC). We analyzed platelet counts, HDL-C, low-density lipoprotein cholesterol (LDL-C), and fasting total cholesterol (TC) using standard protocols, as described previously [34, 35].

Other covariates of interest

Herein, we evaluated a series of possible confounding factors highlighted by epidemiological research and associated with depressive symptoms. Among these factors were sociodemographic variables, namely, marital status, education status, family poverty-to-income ratio (PIR), race, gender and age; as well as physical variables, such as, body mass index (BMI); and lifestyle variables, including alcohol intake, smoking habit, recreational activities and diet status. Additionally, comorbid conditions namely diabetes mellitus (DM), hypertension, chronic kidney disease (CKD), arteriosclerotic cardiovascular disease (ASCVD) and sleep disorder was also investigated.

Attained through self-reported questionnaires, the sociodemographic information underwent intricate categorization. Age delineations included < 45, 45–64, or ≥ 65 years, while race/ethnicity options encompassed non-Hispanic black, non-Hispanic white, Mexican-American, or other, accommodating individuals with multiracial backgrounds. Marital status featured never married, married, or living separately, with divorced, widowed, or separately living individuals grouped under the category of those residing in individual households. Educational status was stratified into below high school (HS), HS graduate, or beyond HS, providing a comprehensive framework for sociodemographic characterization. WHO guidelines were used that BMI ≥ 25 kg/m^2 were designated as overweight, and this included obese individuals. The family PIR, when less than 1.00, indicates that the household income is below the poverty threshold, while a PIR exceeding 3.00 signifies that the income is more than three times the poverty threshold.

The assessment of lifestyle factors was undertaken through the administration of self-reported questionnaires as data collection’s an integral component. Alcohol intake was categorized as follows: lifetime abstainers, consumed < 12 drinks in lifetime; former drinkers, consumed ≥ 12 drinks in lifetime, but no intake in the last year before study; current light drinkers, consumed < 3 drinks each week; and current heavy drinkers, consumed > 3 drinks each week. Based on the NCHS and CDC, patient smoking habit was grouped as follows: never consumed or consumed < 100 cigarettes in lifetime; consumed ≥ 100 cigarettes but quit before interview; current consumers. Vigorous recreational activities were stratified as “yes” or “no” [36]. According to the United States Department of Agriculture (USDA) stratification guidelines, we adjusted the Healthy Eating Index (HEI) total score thresholds as 60, 70, and 80, respectively [37], with > 80 representing “good diet” and ≤ 80 representing “needs improvement”.

Among the analyzed comorbidities were hypertension, DM, CKD, ASCVD and sleep disorder. Hypertension inclusion criteria were hypertension diagnosis, anti-hypertensive drug usage, or systolic blood pressure (BP) ≥ 140 mmHg and/or diastolic BP ≥ 90 mmHg. Type 2 DM utilized the following criteria: a diabetes diagnosis, oral glucose tolerance ≥ 11.1 mmol/L, random glucose content ≥ 11.1 mmol/L, fasting glucose content ≥ 7.0 mmol/L, Hemoglobin A1c (HbA1c) ≥ 6.5%, or antidiabetic drug usage. The Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula was employed to assess the estimated glomerular filtration rate (eGFR) for CKD diagnosis, with CKD indicating eGFR < 60 ml/min/1.73 m^2, or a urine albumin-to-creatinine ratio (UACR) > 30 mg/g [38]. ASCVD and sleep disorder were assessed via self-reported data, with a ‘Yes’ or ‘No’ response.

Statistical analysis

All data analyses employed R 4.2. Following NHANES guidelines, sampling weights were employed to diminish the decisive oversampling of specific demographics. All examinations were weighted for sample size and considered the intricate classified, multistep, cluster sampling approach employed in NHANES [39]. It was attempted to express continuous data in form of mean ± standard error (SE), incorporating adjustments for survey weights, while expression of categorical data was undertaken in form of count and percentage, similarly considering survey weight adjustments. Moreover, herein, we converted the PHR variable from continuous to a categorical scale. Thereafter, several models were developed to assess the individual impacts of PHR and depression symptoms on the outcome of interest. PHR was analyzed as continuous and as categorical variables based on quartiles. The evaluation of inter-group differences, predicated on both PHR quartiles and depressive symptoms, entailed the utilization of the weighted Chi-square test particularly for categorical data and the weighted Student’s t-test distinctly for continuous data.

We also utilized weighted uni- and multivariate logistic regression analyses to examine PHR and depressive symptoms relationship across different models. Crude Model was without flexible adjustments. Model 1 underwent adjustments for patient age, gender and race. Model 2 underwent adjustments for patient age, gender, race, BMI, marital status, family PIR, education status, smoking habit, alcohol intake, recreational activities, diet status, hypertension, CKD, ASCVD, DM, sleep disorder, LDL-C and TC. The P-value for the trend was established using a logistic regression model. Interaction assessments examined association heterogeneity among distinct subgroups. A restricted cubic spline (RCS) model containing three knots explored possible linear and non-linear associations. Knot number 3 selection was completed by minimizing the Akaike information criterion (AIC) statistic. Nonlinear data was assessed with a two-wise linear regression model (segmented regression model), fitting individual intervals while quantifying cut-off influences. The log-likelihood ratio test assessed linear or non-linear associations. Significance cut-off was at p-value < 0.05.

Logistic regression analyses

Using multivariate analysis (Table 2), we exhibited a strong association between exposure and outcome variables, which remained post adjustment of confounding factors (P-value < 0.05). When treated as continuous data, we only identified a significantly direct association between PHR and the likelihood of elevated depressive symptoms in crude model (odds ratio [OR] = 1.02, 95% confidence interval [CI]: 1.01–1.03, P < 0.0001) and model 1 (OR = 1.02, 95% CI: 1.02– 1.03, P < 0.0001). However, no marked relationship was seen between the PHR quartiles and elevated depressive symptoms in the fully adjusted Model 2. As categorical data (divided into quartiles), the largest PHR quartile was directly and significant linked to elevated depressive symptoms relative to the minimum quartile across all models. Especially in fully adjusted model 2, we observed that those with the fourth quartile experienced a drastically raised depressive symptoms by 53% (OR = 1.53, 95% CI: 1.00–2.33, P = 0.05) relative to those with the smallest PHR quartile. However, the P-value for the trend across quartiles was 0.06 in fully adjusted model 2. Additionly, the results of our univariate analysis was shown in Supplementary Table 2

Table 2 Relationship between PHR and depressive symptoms, showed by weighted multivariate logistic regression
Full size table

After full adjustments, we observed an inverted U-shaped relation between PHR and depressive symptoms (Fig. 2). Accordingly, we carried out a two-piece-wise regression model assessment and discovered that this model performed superior to the nonlinear model in explaining the crucial link between PHR and depressive symptoms (log-likelihood ratio (LLR) = 0.06, Table 3). The critical PHR value was 23.76, with PHR range between 0–23.76, PHR increased by 1 unit, the depressive symptoms raised by 0.06 (OR = 1.06, 95% CI: 1.02–1.10, P = 0.01). However, when the range of PHR was ≥ 23.76, the link between PHR and depressive symptoms was insignificant (OR = 1.00, 95% CI: 0.96–1.03, P = 0.85)

Table 3 Results of binary logistic regression and piecewise linear regression model
Full size table

Stratified assessment

Through stratified analysis, each sample in the study was categorized and analyzed independently to ascertain the influence of confounding factors and specific population. As depicted in Table 4, the data suggest that apart from Mexican American, individuals who are never married, those with a history of current or former smoking, and those with a history of former alcohol use, as well as individuals who engage in vigorous recreational activities, have a good diet, or suffer from sleep disorders (P > 0.05), the majority of demographic groups could be a significantly relevant population that is particularly vulnerable to the impact of PHR, which might lead to an increase in depressive symptoms (P < 0.05)

Furthermore, we assessed associations with several patient characteristics—age, gender, race, BMI, marital status, family PIR, education level, smoking status, alcohol intake, recreational activities, diet status, hypertension, CKD, ASCVD, DM and sleep disorders—determine the possibility of strong dependence of the effect modifier on this association. In this report, the association reached significance only amongst gender- and alcohol consumption-stratified population (P for interaction < 0.05), indicating that gender and alcohol use may modify the relationship between PHR and depression symptoms

Table 4 Subgroup analyses of the relationship between PHR values and the risk of depressive symptoms
Full size table

Discussion

We examined the association between PHR and depressive symptoms in this population-based cross-sectional study. Higher PHR index was associated with a higher prevalence of depressive symptoms in the included US adult population, even after adjusting for potential confounders. Additionally, this association remained significant in subgroup analyses. In the RCS analysis, PHR demonstrated a pronounced non-linear association with the risk of elevated depressive symptoms, providing substantial evidence for further clinical and basic research

PHR is a novel combination indicator that evaluates systematic inflammatory of the human body. Despite no prior reports of a link between PHR and depressive symptoms, the relation between HDL-C and depression is widely studied. Based on a cross-sectional investigation involving 64 subjects, circulating HDL-C content is markedly diminished among major depression sufferers [26]. Similar to our conclusions, one prospective investigation revealed that people suffering from anxiety or depression exhibit reduced HDL-C contents, relative to normal controls [40]. According to a Mendelian randomization investigation, diminished HDL-C levels were intricately linked to enhanced depressive symptom risks (OR 2.17, 95% CI 1.40–3.39) [41]. Although, as already mentioned, some earlier studies corroborated with our results, other investigations produced alternate results. For instance, a cross-sectional investigation involving 870 Chinese elderly individuals demonstrated no marked association between HDL-C levels and depression risk [42]. This corroborated another study involving elderly population that also demonstrated no link between the two aforementioned variables [43]. The KNHANES investigation, involving Korean middle-aged adults, reported augmented HDL-C levels among individuals with enhanced depressive symptom risks [44]. Discrepancy in the aforementioned investigations may be due to inherent alterations in subject ethnicity and depression evaluation. Hence, it is crucial to employ reliable inflammatory parameters to enhance elucidation of a potential HDL-C and depression link. In our analyses, the results from the continuous model of PHR and the categorical model were inconsistent. Although the direction for correlation is positive, the results should be interpreted with caution. Based on subcategorical evaluation, subgroup classification by gender and alcohol intake have a strong association with PHR. A recent cross-sectional study in Germany revealed that augmented depressive symptom severity was obvious among medical care patients who consume large quantities of alcohol. Moreover, using interaction analyses, it was revealed that depression risk was steeper among women and younger individuals who consume excess alcohol [45]. Therefore, the mediation effect of gender and alcohol intake in relation PHR and depressive symptoms risk warrants additional exploration

There are limited reports on the associated signaling networks connecting lipid profiles to depression. Cholesterol is a critical modulator of neurological development, and it strictly controls membrane-integrated proteins, ion channels, and synapse formation. One early investigation demonstrated a strong inverse relation between cholesterol and suicidality via the serotonergic (5-HT) system. Circulating cholesterol is also correlated with a transformed inflammatory distribution [46]. Lipid profile dysregulation is common in metabolic syndrome. Prior investigation revealed that inflammatory activation and augmented oxidative stress are common pathways that regulate both metabolic syndrome and depression [3]. GWAS summary data assessment further revealed that cardiometabolic features, such as, HDL-C, LDL-C, TC, and TG exhibit over-lapping genomic loci with depression, which also support the presence of comparable signaling pathways [41]. One review concluded the existence of bi-directional control between HDL-C content and depression risk. Emerging evidences suggest that reduced HDL-C is common among depression sufferers. Alternately, diminished HDL-C content activates inflammatory and oxidative processes to accelerate depression development. In a physiological state, HDL-C removes circulating LPS to suppress macrophage and lymphocyte maturation and activation to reduce inflammation. HDL-C also serves as an antioxidant by downregulating lipid peroxidation while maintaining mitochondrial energy synthesis [21]. Nonetheless, reduced HDL-C content among depression patients dampens these protective influences. The signaling responsible for the initial decline of HDL-C among depression patients warrants further analyses. The NHANES study reported large quantities of proinflammatory cytokines, namely, IL-6, IL-1, and TNF- α, within depressed individuals, which corroborates with a previously proposed signaling network [47]. Herein, we revealed a strong relation between PHR and enhanced depression risk, which is also indicative of a negative reduced HDL-C effect. However, the associated signaling network remains unelucidated and warrants additional exploration

Platelets are non-specific inflammatory indicators that physically associate with leukocytes and the endothelium to modulate inflammatory activity, such as that of cytokines, epinephrine, serotonin, glutamate, dopamine, and P-selectin, within these cells [48]. Serotonin, glutamate, and other proinflammatory molecules, namely, IL-1, CD40L, and P-selectin are secreted from activated platelets, and these, in turn, refulate platelet activity in depressed individuals [49, 50]. Platelets possess glutamate-harboring dense granules [48, 51], and depression is reported to activate platelets. Herein, we revealed that augmented platelet contents are a stand-alone risk factor for depression status

Depression-related risk factors reported previously include obesity, smoking, sleep disorder, DM, hypertension, hyperlipidemia, CKD and ASCVD [52,53,54,55]. A recent systematic review and meta-analysis reported that physically active adults experience reduced depression risk, relative to physically inactive adults [56]. Here, individuals exhibiting symptoms consistent with mild-to-severe depression tended to exhibit a lower education level and household income as compared to subjects without depression. This may indicate that reduced education and household income status are intricately linked to a less healthy lifestyle that includes higher rates of obesity, poor diet, inactivity, smoking, and a failure to comply with medication [57, 58]. Lower levels of education and the consequences thereof may thus partially account for the detected link between inflammation and depression

This investigation has multiple notable strengths. Firstly, we analyzed NHANES information, and suitable NHANES sample weights were fully counted for. Secondly, confounding factors were thoroughly adjusted to increase conclusion reliability and to enable generalizability to a larger population. Thirdly, routine blood and blood biochemistry evaluation provided a cost-effective, simplistic, and extensive information for the diagnosis and management of individuals with elevated depressive symptoms. Therefore, this approach required additional investigation and analyses

Nonetheless, we must discuss the limitations of this investigation. Firstly, due to the design of a cross-sectional study, we were unable to evaluate the causality between PHR and depressive symptoms. Thus, reverse causality may also occur because of the bi-directional relationship between PHR and depressive symptoms. Secondly, while PHQ-9 is a validated screening tool for assessing the frequency of depressive symptoms, it is not suitable for diagnosing clinical depression. Notably, the NHANES database did not include detailed clinical variables such as personal medication histories (both psychotropic and somatic) or comorbid psychiatric disorders (i.e., anxiety and substance use), both of which warrant further investigation. Several investigations, however, have demonstrated strong specificity and sensitivity in PHQ-9-based major depression diagnosis, which may reduce potential assessment errors in our investigation [32, 33]. Additionally, we used NHANES blood samples data from a single blood extraction. Sequential testing could potentially be more indicative of true physiological states, given the lifespan of blood cells. Thirdly, the database has its own internal limitations, such as using self-reported questionnaire to assess other covariates rather than diagnostic interviews for objective measures, which may have introduced confounding factors that influenced the results. Fourthly, given the randomly missing data among the covariables and the large sample size, the study refrained from employing multiple imputation methods to handle the missing data, which may affect the precision of the findings. However, this approach may potentially impact the accuracy of the findings. Lastly, although we detected a statistically significant association between depressive symptoms and PHR, the effect magnitude was very small and therefore may not reflect a clinically relevant relationship

Conclusion

In summary, herein, we revealed a positive link between raised PHR and elevated depressive symptoms risk among US adults when PHR < 23.76. Additional prospective investigations and randomized controlled trials are warranted to validate our findings. The underlying mechanism and potential therapeutic effect still require more investigation

Data availability

The datasets generated and analyzed during the current study are available in the NHANES repository, https://www.cdc.gov/nchs/nhanes/.

References

  1. Malhi GS, Mann JJ, London. England). 2018;392(10161):2299–312.

    Google Scholar 

  2. Liu Q, He H, Yang J, Feng X, Zhao F, Lyu J. Changes in the global burden of depression from 1990 to 2017: findings from the Global Burden of Disease study. J Psychiatr Res. 2020;126:134–40.

    Article  PubMed  Google Scholar 

  3. de Melo LGP, Nunes SOV, Anderson G, Vargas HO, Barbosa DS, Galecki P, et al. Shared metabolic and immune-inflammatory, oxidative and nitrosative stress pathways in the metabolic syndrome and mood disorders. Prog Neuro-psychopharmacol Biol Psychiatry. 2017;78:34–50.

    Article  Google Scholar 

  4. Dowlati Y, Herrmann N, Swardfager W, Liu H, Sham L, Reim EK, et al. A meta-analysis of cytokines in major depression. Biol Psychiatry. 2010;67(5):446–57.

    Article  CAS  PubMed  Google Scholar 

  5. Kim JW, Szigethy EM, Melhem NM, Saghafi EM, Brent DA. Inflammatory markers and the pathogenesis of pediatric depression and suicide: a systematic review of the literature. J Clin Psychiatry. 2014;75(11):1242–53.

    Article  PubMed  Google Scholar 

  6. Capuron L, Miller AH. Cytokines and psychopathology: lessons from interferon-alpha. Biol Psychiatry. 2004;56(11):819–24.

    Article  CAS  PubMed  Google Scholar 

  7. Capuron L, Miller AH. Immune system to brain signaling: neuropsychopharmacological implications. Pharmacol Ther. 2011;130(2):226–38.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Feinstein A, Magalhaes S, Richard JF, Audet B, Moore C. The link between multiple sclerosis and depression. Nat Reviews Neurol. 2014;10(9):507–17.

    Article  Google Scholar 

  9. Stubbs MA, Clark VL, Gibson PG, Yorke J, McDonald VM. Associations of symptoms of anxiety and depression with health-status, asthma control, dyspnoea, dysfunction breathing and obesity in people with severe asthma. Respir Res. 2022;23(1):341.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Najjar S, Pearlman DM, Alper K, Najjar A, Devinsky O. Neuroinflammation and psychiatric illness. J Neuroinflammation. 2013;10:43.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Hodes GE, Kana V, Menard C, Merad M, Russo SJ. Neuroimmune mechanisms of depression. Nat Neurosci. 2015;18(10):1386–93.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Miller AH, Raison CL. The role of inflammation in depression: from evolutionary imperative to modern treatment target. Nat Rev Immunol. 2016;16(1):22–34.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Köhler O, Benros ME, Nordentoft M, Farkouh ME, Iyengar RL, Mors O, et al. Effect of anti-inflammatory treatment on depression, depressive symptoms, and adverse effects: a systematic review and meta-analysis of randomized clinical trials. JAMA Psychiatry. 2014;71(12):1381–91.

    Article  PubMed  Google Scholar 

  14. Haapakoski R, Mathieu J, Ebmeier KP, Alenius H, Kivimäki M. Cumulative meta-analysis of interleukins 6 and 1β, tumour necrosis factor α and C-reactive protein in patients with major depressive disorder. Brain Behav Immun. 2015;49:206–15.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Beydoun MA, Obhi HK, Weiss J, Canas JA, Beydoun HA, Evans MK, et al. Systemic inflammation is associated with depressive symptoms differentially by sex and race: a longitudinal study of urban adults. Mol Psychiatry. 2020;25(6):1286–300.

    Article  PubMed  Google Scholar 

  16. Frank P, Jokela M, Batty GD, Cadar D, Steptoe A, Kivimäki M. Association between Systemic Inflammation and individual symptoms of Depression: a pooled analysis of 15 Population-based Cohort studies. Am J Psychiatry. 2021;178(12):1107–18.

    Article  PubMed  Google Scholar 

  17. Lu CF, Cang XM, Liu WS, Wang LH, Huang HY, Sang SM, et al. Association between the platelet/high-density lipoprotein cholesterol ratio and nonalcoholic fatty liver disease: results from NHANES 2017–2020. Lipids Health Dis. 2023;22(1):130.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Jialal I, Jialal G, Adams-Huet B. The platelet to high density lipoprotein -cholesterol ratio is a valid biomarker of nascent metabolic syndrome. Diab/Metab Res Rev. 2021;37(6):e3403.

    Article  CAS  Google Scholar 

  19. Raison CL, Capuron L, Miller AH. Cytokines sing the blues: inflammation and the pathogenesis of depression. Trends Immunol. 2006;27(1):24–31.

    Article  CAS  PubMed  Google Scholar 

  20. Dietrich-Muszalska A, Olas B. The changes of aggregability of blood platelets in schizophrenia. World J Biol Psychiatry: Official J World Federation Soc Biol Psychiatry. 2009;10(2):171–6.

    Article  Google Scholar 

  21. Morris G, Puri BK, Bortolasci CC, Carvalho A, Berk M, Walder K, et al. The role of high-density lipoprotein cholesterol, apolipoprotein A and paraoxonase-1 in the pathophysiology of neuroprogressive disorders. Neurosci Biobehav Rev. 2021;125:244–63.

    Article  CAS  PubMed  Google Scholar 

  22. van der Stoep M, Korporaal SJ, Van Eck M. High-density lipoprotein as a modulator of platelet and coagulation responses. Cardiovascular Res. 2014;103(3):362–71.

    Article  Google Scholar 

  23. Nofer JR, Brodde MF, Kehrel BE. High-density lipoproteins, platelets and the pathogenesis of atherosclerosis. Clin Exp Pharmacol Physiol. 2010;37(7):726–35.

    Article  CAS  PubMed  Google Scholar 

  24. Pirillo A, Catapano AL, Norata GD. Biological consequences of dysfunctional HDL. Curr Med Chem. 2019;26(9):1644–64.

    Article  CAS  PubMed  Google Scholar 

  25. Enko D, Brandmayr W, Halwachs-Baumann G, Schnedl WJ, Meinitzer A, Kriegshäuser G. Prospective plasma lipid profiling in individuals with and without depression. Lipids Health Dis. 2018;17(1):149.

    Article  PubMed  PubMed Central  Google Scholar 

  26. Maes M, Smith R, Christophe A, Vandoolaeghe E, Van Gastel A, Neels H, et al. Lower serum high-density lipoprotein cholesterol (HDL-C) in major depression and in depressed men with serious suicidal attempts: relationship with immune-inflammatory markers. Acta Psychiatrica Scandinavica. 1997;95(3):212–21.

    Article  CAS  PubMed  Google Scholar 

  27. Oh J, Kim TS. Serum lipid levels in depression and suicidality: the Korea National Health and Nutrition Examination Survey (KNHANES) 2014. J Affect Disord. 2017;213:51–8.

    Article  CAS  PubMed  Google Scholar 

  28. Shin JY, Suls J, Martin R. Are cholesterol and depression inversely related? A meta-analysis of the association between two cardiac risk factors. Ann Behav Med. 2008;36(1):33–43.

    Article  PubMed  Google Scholar 

  29. Ciardullo S, Monti T, Perseghin G. Prevalence of liver steatosis and fibrosis detected by transient Elastography in adolescents in the 2017–2018 National Health and Nutrition Examination Survey. Clinical gastroenterology and hepatology: the official clinical practice. J Am Gastroenterological Association. 2021;19(2):384–e901.

    CAS  Google Scholar 

  30. Vilar-Gomez E, Nephew LD, Vuppalanchi R, Gawrieh S, Mladenovic A, Pike F, et al. High-quality diet, physical activity, and college education are associated with low risk of NAFLD among the US population. Hepatology (Baltimore MD). 2022;75(6):1491–506.

    Article  PubMed  Google Scholar 

  31. Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001;16(9):606–13.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Maske UE, Busch MA, Jacobi F, Beesdo-Baum K, Seiffert I, Wittchen HU, et al. Current major depressive syndrome measured with the Patient Health Questionnaire-9 (PHQ-9) and the Composite International Diagnostic interview (CIDI): results from a cross-sectional population-based study of adults in Germany. BMC Psychiatry. 2015;15:77.

    Article  PubMed  PubMed Central  Google Scholar 

  33. Carey M, Jones KA, Yoong SL, D’Este C, Boyes AW, Paul C, et al. Comparison of a single self-assessment item with the PHQ-9 for detecting depression in general practice. Fam Pract. 2014;31(4):483–9.

    Article  PubMed  Google Scholar 

  34. Ciardullo S, Perseghin G. Statin use is associated with lower prevalence of advanced liver fibrosis in patients with type 2 diabetes. Metab Clin Exp. 2021;121:154752.

    Article  CAS  PubMed  Google Scholar 

  35. Zou B, Yeo YH, Nguyen VH, Cheung R, Ingelsson E, Nguyen MH. Prevalence, characteristics and mortality outcomes of obese, nonobese and lean NAFLD in the United States, 1999–2016. J Intern Med. 2020;288(1):139–51.

    Article  CAS  PubMed  Google Scholar 

  36. Zhang X, Zhao D, Guo S, Yang J, Liu Y. Association between triglyceride glucose index and depression in hypertensive population. J Clin Hypertens (Greenwich Conn). 2024;26(2):177–86.

    Article  CAS  Google Scholar 

  37. Krebs-Smith SM, Pannucci TE, Subar AF, Kirkpatrick SI, Lerman JL, Tooze JA, et al. Update of the healthy eating index: HEI-2015. J Acad Nutr Dietetics. 2018;118(9):1591–602.

    Article  Google Scholar 

  38. Beck LH Jr., Ayoub I, Caster D, Choi MJ, Cobb J, Geetha D, et al. KDOQI US Commentary on the 2021 KDIGO Clinical Practice Guideline for the management of glomerular diseases. Am J Kidney Diseases: Official J Natl Kidney Foundation. 2023;82(2):121–75.

    Article  CAS  Google Scholar 

  39. Akinbami LJ, Chen TC, Davy O, Ogden CL, Fink S, Clark J et al. National Health and Nutrition Examination Survey, 2017-March 2020 Prepandemic File: Sample Design, Estimation, and Analytic Guidelines. Vital and health statistics Ser 1, Programs and collection procedures. 2022(190):1–36.

  40. Huang TL, Wu SC, Chiang YS, Chen JF. Correlation between serum lipid, lipoprotein concentrations and anxious state, depressive state or major depressive disorder. Psychiatry Res. 2003;118(2):147–53.

    Article  CAS  PubMed  Google Scholar 

  41. Torgersen K, Rahman Z, Bahrami S, Hindley GFL, Parker N, Frei O, et al. Shared genetic loci between depression and cardiometabolic traits. PLoS Genet. 2022;18(5):e1010161.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Ji-Rong Y, Bi-Rong D, Chang-Quan H, Yan-Ling Z. Depression and serum lipids and lipoprotein in Chinese nonagenarians and centenarians. J Am Geriatr Soc. 2009;57(4):732–3.

    Article  PubMed  Google Scholar 

  43. Ergün UG, Uguz S, Bozdemir N, Güzel R, Burgut R, Saatçi E, et al. The relationship between cholesterol levels and depression in the elderly. Int J Geriatr Psychiatry. 2004;19(3):291–6.

    Article  PubMed  Google Scholar 

  44. Shin HY, Kang G, Kang HJ, Kim SW, Shin IS, Yoon JS, et al. Relationships between high-density lipoprotein cholesterol and depressive symptoms: findings of the Korean National Health and Nutrition Examination Survey (KNHANES). Psychiatry Res. 2016;241:172–4.

    Article  CAS  PubMed  Google Scholar 

  45. Guertler D, Moehring A, Krause K, Batra A, Eck S, Freyer-Adam J, et al. Copattern of depression and alcohol use in medical care patients: cross-sectional study in Germany. BMJ open. 2020;10(5):e032826.

    Article  PubMed  PubMed Central  Google Scholar 

  46. Parekh A, Smeeth D, Milner Y, Thure S. The role of lipid biomarkers in Major Depression. Healthc (Basel Switzerland). 2017;5(1).

  47. Liaw FY, Kao TW, Hsueh JT, Chan YH, Chang YW, Chen WL. Exploring the link between the components of metabolic syndrome and the risk of Depression. Biomed Res Int. 2015;2015:586251.

    Article  PubMed  PubMed Central  Google Scholar 

  48. Herr DR, Chew WS, Satish RL, Ong WY. Pleotropic roles of Autotaxin in the Nervous System Present opportunities for the development of Novel therapeutics for neurological diseases. Mol Neurobiol. 2020;57(1):372–92.

    Article  CAS  PubMed  Google Scholar 

  49. Bayat M, Zabihi S, Karbalaei N, Haghani M. Time-dependent effects of platelet-rich plasma on the memory and hippocampal synaptic plasticity impairment in vascular dementia induced by chronic cerebral hypoperfusion. Brain Res Bull. 2020;164:299–306.

    Article  CAS  PubMed  Google Scholar 

  50. Karege F, Perret G, Bondolfi G, Schwald M, Bertschy G, Aubry JM. Decreased serum brain-derived neurotrophic factor levels in major depressed patients. Psychiatry Res. 2002;109(2):143–8.

    Article  CAS  PubMed  Google Scholar 

  51. Kalev-Zylinska ML, Green TN, Morel-Kopp MC, Sun PP, Park YE, Lasham A, et al. N-methyl-D-aspartate receptors amplify activation and aggregation of human platelets. Thromb Res. 2014;133(5):837–47.

    Article  CAS  PubMed  Google Scholar 

  52. Fang H, Tu S, Sheng J, Shao A. Depression in sleep disturbance: a review on a bidirectional relationship, mechanisms and treatment. J Cell Mol Med. 2019;23(4):2324–32.

    Article  PubMed  PubMed Central  Google Scholar 

  53. Huang W, Wang Z, Zou C, Liu Y, Pan Y, Lu J, et al. Effects of metabolic factors in mediating the relationship between type 2 diabetes and depression in east Asian populations: a two-step, two-sample mendelian randomization study. J Affect Disord. 2023;335:120–8.

    Article  CAS  PubMed  Google Scholar 

  54. Hamam MS, Kunjummen E, Hussain MS, Nasereldin M, Bennett S, Miller J. Anxiety, Depression, and Pain: considerations in the treatment of patients with uncontrolled hypertension. Curr Hypertens Rep. 2020;22(12):106.

    Article  PubMed  Google Scholar 

  55. Meng R, Yu C, Liu N, He M, Lv J, Guo Y, et al. Association of Depression with all-cause and Cardiovascular Disease Mortality among adults in China. JAMA Netw open. 2020;3(2):e1921043.

    Article  PubMed  PubMed Central  Google Scholar 

  56. Pearce M, Garcia L, Abbas A, Strain T, Schuch FB, Golubic R, et al. Association between Physical Activity and Risk of Depression: a systematic review and Meta-analysis. JAMA Psychiatry. 2022;79(6):550–9.

    Article  PubMed  PubMed Central  Google Scholar 

  57. Panagiotakos DB, Pitsavos C, Chrysohoou C, Tsetsekou E, Papageorgiou C, Christodoulou G, et al. Inflammation, coagulation, and depressive symptomatology in cardiovascular disease-free people; the ATTICA study. Eur Heart J. 2004;25(6):492–9.

    Article  CAS  PubMed  Google Scholar 

  58. Wang K, Zhao Y, Nie J, Xu H, Yu C, Wang S. Higher HEI-2015 score is Associated with reduced risk of Depression: result from NHANES 2005–2016. Nutrients. 2021;13(2).

Download references

Acknowledgements

Thanks to Zhang Jing (Second Department of Infectious Disease, Shanghai Fifth People’s Hospital, Fudan University) for statistical analysis support and for his work on the NHANES database. His outstanding work, nhanesR package and webpage, makes it easier for us to explore NHANES database.

Funding

The work was supported by Zhejiang Provincial Natural Science Foundation of China (LTGG24H310001).

Author information

Authors and Affiliations

  1. Department of Breast and Thyroid Surgery, Affiliated Jinhua Hospital, Zhejiang University School of Medicine, No. 365 Renmin East Road, Wucheng District, Jinhua, Zhejiang Province, 321000, China

    Junjie Ni, Pu Wu, Xiaofeng Lu & Chaoyang Xu

  2. Central Laboratory, Affiliated Jinhua Hospital, Zhejiang University School of Medicine, Jinhua, Zhejiang Province, China

    Xiaofeng Lu & Chaoyang Xu

Authors
  1. Junjie Ni
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Pu Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Xiaofeng Lu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Chaoyang Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

J.J. N. and C.Y. X. put forward the conception and design of the study. J.J. N., P. W., X.F. L. and C.Y. X. collected and analyzed the data. C.Y. X., X.F. L. and J.J. N. made the tables and figures. All the authors drafted and revised the paper. All the authors contributed to the article and approved the final version of the manuscript.

Corresponding authors

Correspondence to Xiaofeng Lu or Chaoyang Xu.

Ethics declarations

Ethics approval and consent to participate

All study participants provided informed consent and the study protocol was approved by the Ethics Review Board of the National Center for Health Statistics (NCHS). Information can be found on the NHANES website (https://www.cdc.gov/nchs/nhanes/ parti cipant. htm).

Consent for publication

Not applicable.

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary Material 1

Supplementary Material 2

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ni, J., Wu, P., Lu, X. et al. Examining the cross-sectional relationship of platelet/high-density lipoprotein cholesterol ratio with depressive symptoms in adults in the United States. BMC Psychiatry 24, 427 (2024). https://doi.org/10.1186/s12888-024-05878-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s12888-024-05878-x

Keywords

BMC Psychiatry

ISSN: 1471-244X

Contact us